Vertex (VRTX) PT Lifted to $180 at Piper Jaffray as KALYDECO and ORKAMBI Both Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Baird Positive on First Quarter of Vertex (VRTX) Orkambi Sales
October 29, 2015 6:58 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $160 price target on Vertex (NASDAQ: VRTX) following results saying they are bullish on first quarter of Orkambi sales.
Skorney commented, "Right off the bat, Orkambi commanded ~35% of the patients eligible for treatment, according... More
Vertex Pharma (VRTX) Misses Q3 EPS by 9c
October 28, 2015 4:02 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q3 EPS of ($0.39), $0.09 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $309.8 million versus the consensus estimate of $245.84 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
... More